Vanda Pharmaceuticals Submits Iloperidone New Drug Application
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia. The application includes data from 35 clinical trials and more than 3,000 patients treated with iloperidone.
